AOD-9604

What Is AOD-9604?

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic 16-amino acid peptide fragment derived from the C-terminal domain of human growth hormone (amino acids 176–191), with a tyrosine residue substituted at the N-terminus for stability. It was developed in the 1990s by Metabolic Pharmaceuticals Ltd. in Australia, based on the hypothesis that the lipolytic (fat-burning) properties of growth hormone could be isolated from its growth-promoting and diabetogenic effects.

The concept was elegant: take only the fat-metabolism portion of GH and discard the rest. In animal models, this worked — AOD-9604 stimulated lipolysis and fat oxidation without raising IGF-1, affecting glucose homeostasis, or binding the GH receptor. In humans, it did not work well enough. AOD-9604’s clinical development was terminated in 2007 after its largest human trial failed to demonstrate statistically significant weight loss.

Despite this failure, AOD-9604 has become one of the most marketed grey-market peptides, frequently sold alongside claims that its evidence does not support.

How It Works

AOD-9604 acts through a mechanism distinct from full-length growth hormone:

Lipolysis stimulation: In animal models, AOD-9604 stimulated hormone-sensitive lipase and inhibited acetyl-CoA carboxylase in adipose tissue, mirroring the lipolytic actions of intact hGH. It also upregulated β3-adrenergic receptor expression in fat cells — β3-AR knockout mice were unresponsive to AOD-9604’s effects, confirming this pathway’s importance.

What it does NOT do: Critically, AOD-9604 does not bind the human growth hormone receptor and does not stimulate IGF-1 production. This means it does not carry the risks associated with exogenous GH therapy (insulin resistance, fluid retention, tissue growth). This selective mechanism was the entire rationale for its development.

The β3-AR problem: The β3-adrenergic receptor plays a more significant role in rodent fat metabolism than in human fat metabolism. Human adipose tissue has lower β3-AR expression than rodent tissue. This species difference likely explains why AOD-9604’s robust animal data did not translate to meaningful human efficacy.

What the Research Actually Shows

Animal Data

The animal evidence is genuinely positive:

Heffernan M et al. (Endocrinology, 2001;142(12):5182–5189): 14 days of AOD-9604 treatment reduced body weight and increased lipolytic sensitivity in obese (ob/ob) mice. The effect was mediated by β3-AR upregulation. β3-AR knockout mice did not respond.

Ng FM et al. (Horm Res, 2000;53 Suppl 1:16–20): AOD-9604 reduced body weight gain and adipocyte cell size in obese Zucker rats over 20 days. Unlike full-length hGH, it did not induce insulin resistance or glucose intolerance.

Heffernan M et al. (Int J Obes, 2001;25(10):1442–1449): Confirmed AOD-9604 increased fat oxidation in obese mice without affecting plasma insulin, glucose, or IGF-1 levels. Confirmed that AOD-9604 does not bind the hGH receptor.

Human Data — The Failure

AOD-9604 completed six human clinical trials involving over 900 participants — making it one of the most thoroughly human-tested grey-market peptides in existence. The safety data is reassuring. The efficacy data is not.

Phase IIb trial (Metabolic Pharmaceuticals, 2007): The pivotal 12-week randomized, placebo-controlled trial in obese subjects. At the 1 mg oral dose, subjects lost an average of 1.8 kg more than placebo (approximately 2.6 kg total vs 0.8 kg placebo). This difference, while statistically significant in some analyses, was not deemed clinically meaningful by the company or regulators. Metabolic Pharmaceuticals terminated development in 2007 based on these results.

Safety profile across all trials: AOD-9604 was well-tolerated with adverse events indistinguishable from placebo. No effect on IGF-1, glucose, or insulin levels was observed. This is the good news about AOD-9604 — it appears quite safe. The bad news is that it also appears to barely work.

What’s Missing

• No evidence of clinically meaningful weight loss in humans — the Phase IIb trial failed to support further development
• No approved indication anywhere in the world
• No human body composition data (lean mass vs fat mass changes)
• Emerging cartilage repair claims are based on preclinical data and small investigator-initiated studies — no published RCT supports this use
• The β3-AR mechanism that drives results in mice may not translate to human fat metabolism due to species-specific receptor expression differences

Safety Profile

Paradoxically, AOD-9604 may have the best-documented safety profile of any grey-market peptide:

Across 900+ participants in six controlled trials: Adverse events were indistinguishable from placebo. No clinically significant effects on glucose, insulin, IGF-1, or any metabolic parameter were observed. Short-term tolerability was excellent.

What this means: AOD-9604 is probably safe. It is also probably ineffective. These two facts are related — a peptide fragment that doesn’t bind the GH receptor and doesn’t raise IGF-1 is unlikely to cause GH-related side effects. It is also unlikely to produce GH-like therapeutic benefits.

Legal and Regulatory Status

FDA: Category 2 — AOD-9604 cannot be legally compounded by 503A or 503B pharmacies. In December 2024, the PCAC voted against including AOD-9604 on the compounding bulks list.

WADA: Prohibited under S2.2.3 (GH Fragments), classified alongside other growth hormone fragments. Banned at all times, in and out of competition.

State enforcement: Ohio Board of Pharmacy has issued summary suspension orders against clinics possessing AOD-9604 alongside BPC-157 and ipamorelin.

Australia (TGA): Originally developed in Australia. The TGA has not approved AOD-9604 for any indication. Metabolic Pharmaceuticals sought GRAS (Generally Recognized As Safe) status for AOD-9604 as a food ingredient — this was granted by the FDA in 2015 for use specifically in combination with food products at very low concentrations, not as a therapeutic peptide. Some vendors misrepresent this GRAS determination as evidence of FDA approval or safety for injectable use.

Common Vendor Claims vs. Reality

What vendors say	What the evidence shows
”Burns fat without affecting muscle”	Animal data supports selective lipolysis; human trials showed clinically insignificant weight loss
”Clinically proven weight loss peptide”	The clinical trial program failed — the company terminated development based on inadequate efficacy
”Safer than HGH”	Probably true — it doesn’t bind the GH receptor. But “safer than HGH” and “effective” are different claims
”FDA GRAS approved”	Misleading — GRAS status was granted as a food ingredient at low concentrations, not as a therapeutic peptide for injection
”Repairs cartilage and joints”	Preclinical data only; no published randomized controlled trial in humans supports this claim
”Can be legally compounded”	False since January 2025 — Category 2, compounding prohibited

The Bottom Line

AOD-9604 is an instructive case study in the gap between animal research and human medicine. The preclinical science was sound: a GH fragment that selectively promotes fat oxidation without the metabolic downsides of full-length GH. The animal data was convincing. The human trials showed it was safe — and also showed it barely worked.

The company that invested millions in developing AOD-9604 walked away from it in 2007. The grey market picked it up and has been selling it ever since, often with claims that exceed what the human clinical data actually demonstrated. When a pharmaceutical company with financial incentive to prove a drug works concludes that it doesn’t work well enough, that is powerful evidence.

AOD-9604 is probably one of the safest grey-market peptides available. It is also probably one of the least effective for its marketed purpose. Whether paying for a safe but likely ineffective peptide represents good value is a judgment call for each individual.

---

This profile will be updated as new research becomes available. Last reviewed: March 2, 2026.